Scribe Therapeutics.
genetic medicine therapeutics company from Alameda, California
- Reports this week
- 0
- Active events
- 0
- Connections
- 14
What's happening
One to three months ago
-
CRISPR Therapeutics and Scribe Therapeutics presented at a Morgan Stanley conference, highlighting their competition in gene-editing therapeutics.Some support1 report
-
Scribe Therapeutics secured funding through a private placement with Sanofi and received grant support from CIRM.Some support1 report
-
Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.Some support2 reports
-
Scribe Therapeutics' shares are set to begin trading on Nasdaq, following an analysis of IPO trends by HSBC.Some support2 reports
-
Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Scribe Therapeutics this week
News at the entities that move Scribe Therapeutics most-
Nasdaq StructuralLyft is listed on Nasdaq, and Cantor Fitzgerald has cut its target price while MarketBeat reports on the stock.Moves Scribe Therapeutics
-
Andreessen Horowitz StructuralInvestors, including Andreessen Horowitz and Thrive Capital, provided funding to Stripe.Moves Scribe Therapeutics
-
Eli Lilly and Company StructuralMedicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.Moves Scribe Therapeutics
-
Wells Fargo TransactionalIndustry leaders from major financial institutions met in Miami on October 19, 2026.Moves Scribe Therapeutics
-
Leerink partners OperationalLeerink Partners is acting as a placement agent for First Tracks Biotherapeutics.Moves Scribe Therapeutics
-
CRISPR Therapeutics OperationalCRISPR Therapeutics announced that A.J. Silver will succeed Raju Prasad as CFO, following Silver's time at Ernst & Young LLP.Moves Scribe Therapeutics
Connections
The 11 strongest of 14, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
Scribe Therapeutics is scheduled to begin trading its shares on the Nasdaq exchange.
-
Andreessen Horowitz Structural
Andreessen Horowitz is identified as a major shareholder of Scribe Therapeutics.
-
Eli Lilly and Company Structural
Eli Lilly provides financial backing for Scribe Therapeutics.
-
Wells Fargo Transactional
Wells Fargo assigned an overweight rating to Scribe Therapeutics.
-
Securities and Exchange Commission Structural
Scribe Therapeutics initiated contact with the SEC regarding plans to achieve public market status.
-
Leerink partners Operational
Leerink Partners actively influenced Scribe Therapeutics by leading its IPO and providing market ratings.
-
CRISPR Therapeutics Operational
The two companies are actively competing against each other in the gene-editing therapeutics market.
-
Yanan Zhu Structural
Yanan Zhu serves as an analyst covering Scribe Therapeutics for Wells Fargo.
Show all 11 connections
History
Events by the month they beganSeptember 2026
2 eventsJuly 2026
3 events- Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.
- Scribe Therapeutics' shares are set to begin trading on Nasdaq, following an analysis of IPO trends by HSBC.
- Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.